

POLICIES GOVERNING ICRF ACCELERATION GRANTS

The mission of the ICRF is to support world class research of high scientific merit and clear potential significance for advancing the understanding, diagnosis or treatment of cancer. Some of the most exciting science does not start out with eventual success assured, but emerges from a high risk/high yield project carried out by a team of creative and dedicated investigators. Acceleration Grants were conceived as a mechanism for encouraging this sort of science, involving innovative approaches by investigators who pioneer new ways of approaching cancer biology and therapeutics. Preliminary data are not a prerequisite, but applicants are encouraged to provide data from disparate sources to support the rationale for the research proposed. Multi-investigator applications and interdisciplinary approaches are encouraged, but not required.

Duration and Amount of the Grant

Acceleration Grants are awarded for two (2) years for \$70,000 per year, as determined by the Scientific Review Panel and the availability of funds. Funding for the second year is contingent upon progress in the preceding funding period, as documented in a progress report due on June 30.

To Apply for an Acceleration Grant

- Letter of Intent (LOI): Because of the innovative focus of the Acceleration Grant program, the ICRF requires that interested investigators submit a letter of intent (LOI) outlining the proposed research in brief, due no later than December 1. LOIs will be reviewed to identify proposals that best fit the goals of the Acceleration Grant program.
- **Submission of a Full Proposal**: Investigators who outline projects of exceptional novelty and promise in the LOI will be invited to submit a full proposal, due January 15. Notification of funding will occur May 1 or thereafter.

Application Templates

Templates for applying for an ICRF cancer research grant can be downloaded from: <u>https://proposalcentral.com/default.asp</u>.

Further Information

Current information on categories of grants currently available and on **General Policies Governing ICRF Grants**, including fiscal requirements for sponsoring institutions, is available on our website: https://www.icrfonline.org/grants/.

Questions? For any questions or problems, please send an E-mail message to: ellen.rubin@icrfonline.org



GENERAL POLICIES GOVERNING ICRF GRANTS

The Israel Cancer Research Fund (ICRF) supports basic, translational, and clinical cancer research. All research must be conducted in Israel, except in the case of clearly-identified, international collaborative grants. To apply for an ICRF grant, an investigator must be a citizen of Israel (proof of Israeli citizenship must be furnished upon request).

Application Submission and Grant Activation:

RECEIVED BY THE ICRF	NOTIFICATION OF DECISION	ACTIVATION OF GRANT
January 5, 2023, 11:59PM EST	May 1 and thereafter	September 1, 2023

Please note that:

- ICRF's Scientific Review Panels evaluate applications, scoring each in the range of 1-5, with 1 being the highest score.
- Applicants will be notified of funding priority rather than a numerical score. As an approximate guide, funded applications received numerical scores in the range of 1-2; and applications not funded received scores from 2-5.
- ICRF makes an initial round of funding commitments to applications with the very top scores. Subsequent funding commitments are announced individually, depending upon availability of funds.
- Applications that are not funded when initially submitted may become competitive upon revision and resubmission.

Important Points Regarding Application Submission:

- Applications that do not provide all required information, as specified, will be rejected automatically, and will not be processed or reviewed.
- Only one (1) application per principal investigator will be accepted for each submission deadline.
- An individual may be principal investigator on only a single ICRF grant at any given time.
- Typically, a principal investigator currently funded by ICRF may apply for another ICRF grant only if the start date is after the current funding period ends.
- Once an application has been submitted to ICRF, the email addresses for all investigators and institutional personnel contained within the application will be added to the ICRF email list and those individuals will receive regular updates and other important information. Recipients will have the option to unsubscribe from said emails.

Each application is reviewed by an ICRF Scientific Review Panel and evaluated for:

- Scientific merit, innovation, and potential significance for advancing the understanding, diagnosis and/or treatment of cancer.
- Scientific productivity of the applicant, based on the record of publications on research funded by ICRF and other funding agencies; and qualifications of the applicant, based on prior training and demonstrated expertise.
- Facilities, materials, resources and scientific environment available for the project, and the duration of such availability, as identified by the investigator and confirmed in writing by the institutional grants office and/or the investigator's department chair.
- Career Development Awards: soundness of the mentoring plan and letters of commitment from mentors.

The priority rankings and recommendations of the Scientific Review Panels are presented to the International Scientific Council for further consideration and then to the ICRF Board of Trustees for final approval.

Fiscal Requirements and Considerations for the Sponsoring Institution:

An applicant for ICRF funding must hold a position at a sponsoring Israeli institution able to provide research space and administrative infrastructure for the project.

Each submitted application must be signed by both the applicant and an authorized institutional official signifying the ability and willingness of the sponsoring institution to provide research space and budgetary oversight to the project.

ICRF funds may typically only be used for research work performed in Israel, unless the funding opportunity is explicitly identified as an international collaborative grant.

ICRF funds are to be used for actual direct expenses (salary, supplies, etc.) connected with the project. ICRF will not support any overhead, clerical, or other administrative expenses, and institutions may not charge such expenses to the ICRF account.

Travel expenses are allowed only for Career Development Awards to early-career investigators, who may budget up to \$1,000 per year in travel expenses.

The sponsoring institution must maintain a separate account for each grant funded by the ICRF. This account must be available for audit at any time by representatives of the ICRF.

The sponsoring institution must provide an annual Expenditure Report detailing the utilization of all funds expended (salaries, supplies, etc.). This report is due by September 30. Payment of funds will be suspended, if the Expenditure Report is overdue.

Continuation of Funding:

Investigators must document progress in an annual report due on June 30. Funds are initially provided for one year, with funding for subsequent years contingent upon progress as described in this report. Payment of funds will be suspended, if a Progress Report is overdue.

Renewal of Funding:

The ICRF permits renewal of Project Grants and Research Professorship Grants, but not other grant categories. Renewal applications are evaluated by the Scientific Review Panels along with applications for new funding, and they must be competitive with those applications to be renewed. Renewal applications should be submitted by the December 31 deadline during the final active year of the grant to avoid a lapse in funding.

Leave:

Special leave for work in another institution with continuing support from an ICRF grant may be permitted, if directly related to the purpose of the grant. Such leave may not exceed 12 months. If a leave does not exceed three months, only local institutional approval is required. For a longer period, prior approval of the ICRF is required. To obtain approval, the grantee must submit to the ICRF a letter requesting leave that describes how the grantee will supervise his/her laboratory during this period. This letter must be countersigned by the grantee's department head and the appropriate institutional official, and received by ICRF at least six (6) months prior to the requested leave.

Leave without continuing ICRF support requires the prior approval of the ICRF and will be permitted only in unusual situations. Such leave may not exceed 12 months. Support from other sources is permissible during the period of leave, and such leave does not reduce the total number of months of program support for which a grantee is eligible.

Special Conditions:

Should the ICRF grantee or the sponsoring institution specified by a grant vacate the project, the ICRF will automatically void the grant and terminate funding. Failure of the sponsoring institution to notify the ICRF of such vacancy will allow the ICRF to recover funds in toto.

Changes and Amendments:

Any changes or amendments to the scientific goals of the original application or addition or removal of key personnel must be approved in writing by the ICRF.

Termination or Change of Institution:

- 1. If a grantee institution plans to terminate a grant, the ICRF must be notified in writing at the earliest possible time so that appropriate instructions can be given for termination.
- 2. If an individual is moving to another eligible institution, grant support may be continued, provided that:
 - a. A new application is submitted by the new institution on behalf of the individual for review by the ICRF together with a letter of release from the existing institution;
 - b. The period of support requested is only for the time remaining within the duration of overall funding;
 - c. The new application is submitted at least six (6) months prior to the requested effective date to allow the necessary time for review.
- 3. The ICRF may discontinue funding upon determination that the purpose or terms of the grant are not being fulfilled. In the event a grant is terminated, the ICRF shall notify the sponsoring institution and the grantee in writing of its decision, the reasons therefore, the effective date, and the right to appeal the decision.
- 4. A final Progress Report and Expenditure Report are required within 60 days of termination of a grant.

Biohazards and Protection of Human and Animal Subjects:

It is the responsibility of the institution that sponsors a grant to provide oversight that safeguards the rights and welfare of human and animal subjects of research supported by the ICRF, and to ensure that investigators use caution in dealing with any toxic materials or potential biohazards.

Applications for research involving human subjects and/or animals require prior review and approval of the appropriate institutional committee. Approvals <u>must be written in English</u> and submitted along with the ICRF application. For this certification to be valid, the date of the review may not precede the submission date by more than one year.

Patents:

No patent application for research supported by ICRF funds shall be filed by the sponsoring institution or by any individual investigator engaged in this research without prior consultation with and written approval of the ICRF.

Publications:

Publications resulting from ICRF funding must contain the following acknowledgment: "This study was supported by {<u>insert grant category</u>} from the Israel Cancer Research Fund." (Please note that our name ends in "Fund," not "Foundation!")

Grantees should send pdf copies of publications carrying the above credit line by email to the ICRF International Executive Office in New York immediately after the publication appears online.

#

Additional information and templates for applying for an ICRF research grant can be downloaded from our website, <u>https://www.icrfonline.org/grants/</u>, or from <u>https://proposalcentral.com/default.asp</u>.

Questions? For any questions or problems, please send an E-mail message to: ellen.rubin@icrfonline.org